{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:22:54Z","timestamp":1789010574623,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Current prognostic models for peripheral T\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (<jats:styled-content style=\"fixed-case\">SEER<\/jats:styled-content>)\u201018 database to evaluate factors affecting overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) of <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> in the modern era and identified 8802 patients between 2000\u20132010. Most subtypes of <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> increased in incidence during the study period. In univariate analyses, age &gt;55\u00a0years, black race, advanced stage, absence of extra\u2010nodal disease, omission of radiation therapy (<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>) and high\u2010risk histology each predicted inferior <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b70001). Multivariate analysis (<jats:styled-content style=\"fixed-case\">MVA<\/jats:styled-content>) demonstrated that hepatosplenic, enteropathy\u2010associated and extra\u2010nodal Natural Killer\/T cell histologies, each had hazard ratios &gt;1\u00b75 (<jats:italic>P<\/jats:italic>\u00a0\u2264\u00a00\u00b70001) for death. Further, age \u226555\u00a0years, black race and advanced stage maintained their significance in the <jats:styled-content style=\"fixed-case\">MVA<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b70001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> ranging from 9\u00a0months (highest risk group) to 120\u00a0months (lowest risk group). In summary, this is the largest study of <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.<\/jats:p>","DOI":"10.1111\/bjh.13202","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T05:16:39Z","timestamp":1415423799000},"page":"708-718","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Factors predicting survival in peripheral T\u2010cell lymphoma in the <scp>USA<\/scp>: a population\u2010based analysis of 8802 patients in the modern era"],"prefix":"10.1111","volume":"168","author":[{"given":"Adam M.","family":"Petrich","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Northwestern University Chicago IL USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene B.","family":"Helenowski","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Locke J.","family":"Bryan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Northwestern University Chicago IL USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaina A.","family":"Rozell","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Northwestern University Chicago IL USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Galamaga","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Advocate Lutheran General Hospital Park Ridge IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology Department of Medicine The University of Chicago Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802455867"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23144"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.660"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.22.1933"},{"key":"e_1_2_7_8_1","volume-title":"Instructions to Ibm 650 Programmers in Processing Survival Computations, Technical. End Results Evaluation Section","author":"Ederer F.","year":"1959"},{"key":"e_1_2_7_9_1","first-page":"1795","article-title":"Radiation therapy in peripheral T\u2010cell lymphoma of the head and neck","volume":"122","author":"Fernandes A.T.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-012-0136-z"},{"key":"e_1_2_7_13_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq359"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.5.388"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1198\/jasa.2011.ap10243"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227579"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.317"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1309\/QF6N-VAQW-N74H-4JE2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.033"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006277"},{"key":"e_1_2_7_24_1","first-page":"336","article-title":"HTLV\u20101 and associated adult T\u2010cell leukemia\/lymphoma","volume":"7","author":"Mahieux R.","year":"2003","journal-title":"Reviews in Clinical and Experimental Hematology"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.542596"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3472"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8507","article-title":"Belinostat, a novel pan\u2010histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T\u2010cell lymphoma (R\/R PTCL): results from the BELIEF trial","volume":"31","author":"O'Connor O.A.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32832b89a9"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.11.225"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.10.025"},{"key":"e_1_2_7_33_1","first-page":"4264","article-title":"Trends in incidence and outcome in T\u2010cell lymphoma since 1992: A SEER database analysis","volume":"120","author":"Petrich A.M.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_7_37_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-453233"},{"key":"e_1_2_7_40_1","first-page":"811a","article-title":"International Peripheral T\u2010cell Lymphoma (PTCL) Clinical and Pathology Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines","volume":"106","author":"Vose J.","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.08.015"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13202","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:08:18Z","timestamp":1696223298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,7]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/bjh.13202"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13202","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,7]]},"assertion":[{"value":"2014-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}